Protein tyrosine phosphatase type IVA 2 (PTP4A2)

Protein tyrosine phosphatase type IVA 2 (PTP4A2), also known as PRL-2, is a prenylated enzyme belonging to the protein tyrosine phosphatase family. It is localized to the inner leaflet of the plasma membrane and early endosomes, where it regulates essential cellular processes such as proliferation and migration (UniProt, 2024). A key biological function of PTP4A2 is its role as a regulatory subunit for CNNM magnesium transporters, thereby controlling intracellular magnesium homeostasis which is vital for metabolic activity (Hardy et al., 2015). In oncology, PTP4A2 is recognized as an oncoprotein that is frequently upregulated in various malignancies, including breast and prostate cancers, promoting epithelial-to-mesenchymal transition and metastasis (NCBI, 2024). Because of its role in tumor progression, it is a target of interest for small molecule drug development, although high homology with other PRL isoforms presents a significant selectivity challenge. While no specific drugs are currently approved, compounds like pentamidine and experimental inhibitors such as JMS-053 have shown efficacy in inhibiting its activity in research settings (PubMed, 2024). Therapeutic strategies often focus on either inhibiting its catalytic site or disrupting its interaction with magnesium transporters to starve cancer cells of necessary ions.

Other names

PRL-2PTP-CAAX2OV-1Protein-tyrosine phosphatase of regenerating liver 2PTP4A2

Inhibition of the catalytic phosphatase activity and disruption of the protein-protein interaction with CNNM magnesium transporters to modulate intracellular magnesium levels and oncogenic signaling pathways (Hardy et al., 2015; PubMed, 2024).